Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06053242 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

A Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease, sponsored by Creative Medical Technology Holdings.

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT06053242 is a Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease that is actively recruiting participants, run by Creative Medical Technology Holdings. The registered enrollment target is 45 participants, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06053242, a Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease, is actively recruiting participants, sponsored by Creative Medical Technology Holdings.

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.

Interventions

  • OTHER Placebo
  • DRUG CELZ-201-DDT

Study Locations (1)

Florida

  • Spine and Wellness Centers of America - Aventura

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2024-05-21
Est. Completion 2027-05-01
Phase Phase 1

What the Registry Record Tells You About NCT06053242

The ClinicalTrials.gov registry entry for NCT06053242 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (92% lower). The listed sponsor is Creative Medical Technology Holdings, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06053242 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06053242 about?

NCT06053242 is a clinical study titled "Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain". The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.

What is the current status of trial NCT06053242?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-05-21. Estimated completion is 2027-05-01.

What conditions does trial NCT06053242 study?

This clinical trial studies the following conditions: Chronic Low Back Pain, Degenerative Disc Disease.

What interventions are being tested in trial NCT06053242?

The interventions under investigation include: Placebo (OTHER), CELZ-201-DDT (DRUG).

Who is sponsoring clinical trial NCT06053242?

This trial is sponsored by Creative Medical Technology Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06053242 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.